# b-One

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/b-one

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.cn.b1.co
- Latest round: Series B (Dec 28, 2022)
- Investors on record: 5

## About

Established in 2017 and based in Beijing, China, b-One is a medical device company that focuses on development of joint prosthesis products. Mark Kester, PhD, the company’s chief scientist, is the former global senior research director of Stryker. Imants Liepins, the company’s senior R&D director is the former R&D director of ZimmerBiomet and Stryker. The company has branches in Shanghai, Suzhou and Bristol. By 2022, b-One has about 200 employees.

The company's main products are joint prosthesis products, including total knee system, femoral hip system and primary acetabular system. It also provides a limb salvage plan for bone tumors, including pelvic side, femur, tibia, calcaneus and talus, humerus, scapula, finger, radius and ulna and other limb bones.

## Funding rounds

- Series B, Dec 28, 2022 — SPDB International Capital
- Series B, Apr 2, 2021 — Eight Roads Ventures, Agricultural Bank of China, Hubei High Technology, Huatai Zijin Investment
- Series A, Apr 26, 2018 — Eight Roads Ventures

## Investors

- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B
- Agricultural Bank of China — Series B
- Hubei High Technology (https://capitalatlas.ai/funds/hubei-high-technology) — Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- SPDB International Capital (https://capitalatlas.ai/funds/spdb-international-capital) — Series B